Akero Therapeutics Inc (STU:0K4)
€ 29.02 -1.63 (-5.32%) Market Cap: 2.04 Bil Enterprise Value: 1.40 Bil PE Ratio: 0 PB Ratio: 3.02 GF Score: 34/100

Akero Therapeutics Inc Phase 2B HARMONY Trial Data Presentation Transcript

Sep 13, 2022 / 12:00PM GMT
Release Date Price: €28 (+143.48%)
William White
Akero Therapeutics - EVP, CFO, Treasurer & Head of Corporate Development

Presentation
Sep 13, 2022 / 12:00PM GMT

=====================
Corporate Participants
=====================
* William White
Akero Therapeutics - EVP, CFO, Treasurer & Head of Corporate Development
* Andrew Cheng
Akero Therapeutics - President, CEO & Director
* Kitty Yale
Akero Therapeutics - EVP & Chief Development Officer
* Tim Rolph
Akero Therapeutics - Co-Founder & Chief Scientific Officer

=====================
Conference Call Participants
=====================
* Eric Joseph
JPMorgan Chase & Co - Analyst
* Ed Nash
Canaccord Genuity Corp - Analyst
* Ed Arce
H.C. Wainwright & Co, LLC - Analyst

=====================
-

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot